Intrexon Corporation (NYSE:XON) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS
Intrexon Corporation (NYSE:XON) posted its quarterly earnings results on Wednesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05, Briefing.com reports. The firm had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative net margin of 76.32% and a negative return on equity of 21.19%. The firm’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.42) earnings per share.
Intrexon Corporation (NYSE XON) traded up 1.55% during mid-day trading on Wednesday, reaching $20.98. 987,342 shares of the company’s stock traded hands. The stock’s market capitalization is $2.51 billion. Intrexon Corporation has a 12 month low of $18.41 and a 12 month high of $32.90. The firm’s 50-day moving average price is $23.41 and its 200 day moving average price is $22.07.
TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/intrexon-corporation-nysexon-issues-quarterly-earnings-results-beats-expectations-by-0-05-eps/1466804.html.
Several hedge funds and other institutional investors have recently modified their holdings of XON. Dimensional Fund Advisors LP boosted its position in shares of Intrexon Corporation by 670.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 83,514 shares of the biotechnology company’s stock worth $2,029,000 after buying an additional 72,675 shares during the last quarter. Norges Bank bought a new position in shares of Intrexon Corporation during the fourth quarter worth about $17,300,000. Teachers Advisors LLC boosted its position in shares of Intrexon Corporation by 6.4% in the fourth quarter. Teachers Advisors LLC now owns 50,172 shares of the biotechnology company’s stock worth $1,219,000 after buying an additional 3,005 shares during the last quarter. Peregrine Capital Management LLC boosted its position in shares of Intrexon Corporation by 30.2% in the first quarter. Peregrine Capital Management LLC now owns 523,299 shares of the biotechnology company’s stock worth $10,586,000 after buying an additional 121,322 shares during the last quarter. Finally, Creative Planning boosted its position in shares of Intrexon Corporation by 62.1% in the first quarter. Creative Planning now owns 22,308 shares of the biotechnology company’s stock worth $442,000 after buying an additional 8,547 shares during the last quarter. 84.38% of the stock is owned by institutional investors.
Several analysts recently issued reports on XON shares. Zacks Investment Research raised shares of Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a report on Tuesday, May 2nd. BidaskClub upgraded shares of Intrexon Corporation from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 15th. Finally, Northland Securities set a $30.00 target price on shares of Intrexon Corporation and gave the company a “buy” rating in a research note on Monday. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Intrexon Corporation has a consensus rating of “Hold” and an average target price of $40.50.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.